Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study

Edward Millgate,1 Eugenia Kravariti,1 Alice Egerton,1 Oliver D Howes,1 Robin M Murray,1 Laura Kassoumeri,1 Jacek Donocik,1 Shôn Lewis,3,4 Richard Drake,3,4 Stephen Lawrie,5 Anna Murphy,3,4 Tracy Collier,1 Jane Lees,3,4 Charlotte Stockton-Powdrell,3 James Walters,6 Bill Deakin,3 James MacCabe1,2

ABSTRACT

Background 70%–84% of individuals with antipsychotic treatment resistance show non-response from the first episode. Emerging cross-sectional evidence comparing cognitive profiles in treatment resistant schizophrenia to treatment-responsive schizophrenia has indicated that verbal memory and language functions may be more impaired in treatment resistance. We sought to confirm this finding by comparing cognitive performance between antipsychotic non-responders (NR) and responders (R) using a brief cognitive battery for schizophrenia, with a primary focus on verbal tasks compared against other measures of cognition.

Design Cross-sectional.

Setting This cross-sectional study recruited antipsychotic treatment R and antipsychotic NR across four UK sites. Cognitive performance was assessed using the Brief Assessment of Cognition in Schizophrenia (BACS).

Participants One hundred and six participants aged 18–65 years with a diagnosis of schizophrenia or schizoaffective disorder were recruited according to their treatment response, with 52 NR and 54 R cases.

Outcomes Composite and subscale scores of cognitive performance on the BACS. Group (R vs NR) differences in cognitive scores were investigated using univariable and multivariable linear regressions adjusted for age, gender and illness duration.

Results Univariable regression models observed no significant differences between R and NR groups on any measure of the BACS, including verbal memory (β=−1.99, 95% CI −6.63 to 2.66, p=0.398) and verbal fluency (β=1.23, 95% CI −2.46 to 4.91, p=0.510). This pattern of findings was consistent in multivariable models.

Conclusions The lack of group difference in cognition in our sample is likely due to a lack of clinical distinction between our groups. Future investigations should aim to use machine learning methods using longitudinal first episode samples to identify responder subtypes within schizophrenia, and how cognitive factors may interact within this.

Trail registration number REC: 15/LO/0038.

INTRODUCTION

Up to one-third of patients with a schizophrenia diagnosis have inadequate symptomatic improvement despite having at least two antipsychotic drugs, one being a second-generation antipsychotic excluding clozapine, at adequate doses and duration (4–6 weeks; National Institute of Health and Care Excellence (NICE) guidelines) and are termed treatment resistant (TRS).2,3 Almost all guidelines recommend the antipsychotic clozapine in TRS4 with earlier clozapine treatment associated with better outcomes.5–8 There is increasing evidence that TRS may represent a distinct subtype in schizophrenia.9–10 Most treatment resistant cases exhibit antipsychotic non-response (NR) from the first episode with this observed in 70%–84% of patients.3,11 An earlier age of onset has also been consistently associated with antipsychotic treatment resistance,12–16 suggesting that TRS and NR may be associated with neurodevelopmental impairment. Identifying these underlying factors associated with antipsychotic treatment resistance...
in schizophrenia is therefore important for improving prediction and early treatment of NR and TRS.

Cognitive impairment in schizophrenia may provide some insight into antipsychotic treatment response. Performance on tasks of verbal memory has often been reported to be impaired in schizophrenia samples, those prior to medication initiation and at first episode. Indeed, impairments in verbal memory and language functions have also been reported in unaffected first-degree relatives of schizophrenia patients relative to healthy controls. Verbal memory and verbal working memory functions have also been reported to show a protracted maturation into adulthood, with impairments in these functions observed in both early and late schizophrenia. This suggests a possibility of a genetic and cognitive continuum of risk in schizophrenia, which increases from controls to first-degree relatives, to treatment responsive schizophrenia. A broader hypothesis is that treatment resistance is aetiologically continuous with treatment responsive schizophrenia but occupies a more exaggerated position on a continuum of neurodevelopmental liability.

In a recent meta-analysis comparing mostly cross-sectional studies of treatment resistant cases and responders, TRS cases exhibited greatest cognitive impairments on tasks of verbal memory and learning (dL < -0.59, p < 0.001) and language functions (dL < -0.53, p < 0.001), with smaller but still statistically significant impairments in tasks across other cognitive domains, relative to their responder counterparts. However, this meta-analysis included an array of cognitive tasks, many with long test duration and stringent training requirements for raters. Short and comprehensive measures of cognitive performance may aid in the detection of neuropsychological differences between antipsychotic responders (R) and non-responders (NR), while also being cost-effective. The Brief Assessment of Cognition in Schizophrenia (BACS) was originally developed to be an easily administrable, brief, test battery that efficiently and specifically assesses cognitive deficits in schizophrenia cases. The measures included in the battery correspond to several cognitive domains with established deficits in schizophrenia, executive functions, working memory, motor/processing speed, verbal memory, verbal fluency and attention. If observable differences between antipsychotic R and NR are identified, this would further improve our understanding of cognitive factors implicated in the aetiology of antipsychotic response. Likewise, this would raise the possibility for future prospective research to use brief cognitive testing as part of predictive/diagnostic models for antipsychotic response and future treatment resistance.

Therefore, this cross-sectional study sought to assess the cognitive profiles of antipsychotic R and NR using the BACS. Based on the existing literature, we hypothesised that TRS patients would have poorer performance across BACS tasks, particularly on verbal memory and verbal fluency measures.

METHODS
Design
The study used a cross-sectional design comparing antipsychotic treatment R and antipsychotic NR on cognitive performance.

Setting
The study was part of ‘Schizophrenia: Treatment Resistance and Therapeutic Advances’ (STRATA), a consortium which included King’s College London (London, UK), University of Manchester (Manchester, UK), Cardiff University (Wales, UK) and University of Edinburgh (Scotland, UK). The aim of the STRATA consortium is to identify neurobiological, cognitive and genetic biomarkers of antipsychotic treatment resistance and NR within schizophrenia and other related psychotic disorders.

Patient and public involvement
During the early development of the study the views and recommendations of service users and carers regarding the use of stratified medicine research were assessed. Consultations were undertaken with the Institute of Psychiatry, Psychology and Neuroscience’s Service User Advisory Group. Service user researchers in London, Manchester and Edinburgh (18 people) carried out focus groups, and one carer focus group in London (8 people). Focus groups were digitally recorded, the transcripts analysed in NVivo V.10 using a simple thematic analysis, and quotations deidentified to protect participants. The results of this research are published in BioMed Central. Both service users and carers reflected enthusiasm for stratified medicine. Each stage of the study was discussed, including their willingness to participate and attitudes towards, and perceived intrusiveness of different procedures. These individuals also aided in commenting and providing recommendations on consent and participant information forms.

Participants
One hundred and six participants were recruited following a screening of patients across four sites: King’s College London (N = 38), University of Manchester (N = 32), Cardiff University (N = 16) and University of Edinburgh (N = 18). Inclusion criteria were as follows: aged 18–65 years, with a schizophrenia or schizophreniform disorder diagnosis as per Diagnostic and Statistical Manual of Mental Disorders, fifth edition criteria and be able to read and write English to a sufficient level (see also Egerton et al). Participants were excluded if they were pregnant, had ever experienced a head injury involving loss of consciousness for more than 5 min, met International Classification of Diseases (ICD) criteria for harmful substance misuse or a psychotic disorder secondary to substance use, scored <3 on the CRS (a measure of adherence) or had been treated with clozapine in the previous 3 months. All participants gave informed consent prior to enrolment.
Definition of antipsychotic R and antipsychotic NR

Participants were defined as antipsychotic treatment R if they had been treated with only one antipsychotic drug since illness onset or if their antipsychotic drug had been changed only for reasons of adverse effects as opposed to NR. In addition to this, responders needed to have a Clinical Global Impression-Schizophrenia Scale (CGI-SCH) of below 4 (moderately ill), a Positive and Negative Syndrome Scale (PANSS) total score below 60, and a CRS level of adherence greater than 3 (>accepts only because compulsory). Fifty-four treatment responders were recruited into the study.

Antipsychotic treatment NR was defined as having documented treatment with at least two antipsychotics each above the minimum therapeutic dose as defined by the British National Formulary for >4 weeks each, a CGI-SCH severity score of >3, a PANSS total severity rating of at least 70, and a CRS adherence score of >3. Fifty-two participants met criteria for antipsychotic NR.

MATERIALS

Clinical and demographic measures

Previous and existing drug use were measured using the Alcohol, Drug and Tobacco Inventory. Participants’ disorder severity was measured using the Mini-International Neuropsychiatric Interview (M-Psychotic Disorders; A-Major Depressive Episode; D-Manic/Hypomanic/Bipolar). Structured Clinical Interview-PANSS (SGI-PANSS) and CGI-SCH. Concordance with medication was assessed using the Clinical Rating Scale (CRS) for Schizophrenia. Participants also provided demographic data, such as years of previous full-time education, age, gender, as well as information regarding their previous antipsychotic history which were supplemented by medical records.

Measures of cognitive performance

Cognitive data were collected using the BACS across all sites at the beginning of the assessment, following the administration of clinical and demographic measures. The battery is designed to take ~30 min to complete, with minimal training demands, and is designed to be easily administered by clinical and healthcare workers. The BACS (version A) consists of six tests from the following cognitive domains: (1) Verbal Memory: List learning task; (2) Working Memory: Digit Sequencing task; (3) Motor Speed: Token motor task; (4) Verbal Fluency: Category instances task (Animals) and phonological (F and S-words); (5) Attention and speed of information processing: Symbol Coding task; (6) Executive Functions: Tower of London task. All tasks on the BACS are scored with higher scores representing better performance. Composite z and t scores for the BACS are generated using normative data and the following

\[
\text{Composite z score} = \frac{\sum (\text{raw score} - \text{normative score})}{\text{normative standard deviation}}
\]

with each measure’s z score summed and the total divided by 3.63; Composite t score = (Composite z score + 10) + 50.

Data analysis

All analyses were conducted using STATA V.15/SE. χ² tests were used to compare cognitive performance across sites in case of site differences. Univariable regressions were used to compare cognitive performance between groups. Multivariable regression analyses were used to adjust univariable results for age, gender and illness duration, due to the reported relationship of age, gender and illness duration with cognitive outcomes. Analyses adjusting for anticholinergic effects of antipsychotic medication are presented in online supplemental material (online supplemental table S1).

RESULTS

Descriptive statistics of demographic and clinical variables between responder groups are reported in table 1. In the antipsychotic R group (N=54), four were treated with a first-generation antipsychotic. For the NR group (N=52), five were treated with a first-generation antipsychotic. All other participants were treated with second-generation antipsychotics.

Cognitive performance

Mean scores for each group on all BACS tasks and standardised composite scores are displayed in table 2. All measures of the BACS were normally distributed, with exception of the Tower of London task which was moderately negatively skewed (skewness = −0.95) as per the guidelines from Bulmer. Cognitive performance on BACS composite and subtests did not significantly differ by site where data were collected.

Univariable linear regression analyses (table 2) observed no significant relationships between response status and BACS performance. Multivariable models adjusted for age, gender and illness duration also observed no significant relationships between response status and cognitive outcomes (table 2).

DISCUSSION

The present investigation sought to compare specific cognitive deficits in antipsychotic R and antipsychotic NR using the BACS, anticipating the greatest deficits for NR in measures of verbal memory and verbal fluency when compared with R. Unlike previous cross-sectional studies, this investigation identified no significant differences in cognitive performance between groups.

Previous cross sectional research investigating differences in cognitive performance between antipsychotic treatment R and treatment resistant cases have identified poorer performance in verbal, executive function, full-scale IQ cognitive measures, and verbal memory in treatment resistant patients. A recent study using a similar methodology and sample size to ours
also failed to show significant differences between antipsychotic R and TRS cases on individual tasks of the BACS but did observe significant differences on standardised (z and t) composite scores suggesting overall impairment in the TRS group. Our additional analyses also adjusting for anticholinergic effects (online supplemental table S1) also observed no change to the relationship between BACS and antipsychotic response, suggesting no medication effects on our findings. We also further restricted our analysis to exclude participants that were under dosed (ie, not within the 150–600 mg/per day range) removing 12 participants (R=5, NR=7). No change was observed in the pattern of results.

The lack of significant differences in cognitive performance observed between R and NR groups in our study may be partly explained by the criteria used to define these groups. Unlike earlier investigations, our study did not include clozapine-treated patients, and there may have been less clinical separation between the R and NR groups than in some previous studies (as discussed in Egerton et al). Furthermore, in our cross-sectional study design, it is not possible to determine the proportion of participants in the NR group who would meet criteria for TRS. It is, therefore, possible the NR group was less severely unwell as in some previous studies, which may have reduced the ability to observe potential impairments in cognition due to clinical overlap. Previous investigations which observed group differences in cognitive performance between R and TRS included patients prescribed clozapine, and reported higher PANSS positive, negative and total scores, suggesting the NR/TRS groups may have had greater illness severity compared with our sample. Likewise, demographic and clinical variables previously found to be associated with antipsychotic R, such as a younger age and age of illness onset in NR, did not differ between treatment R and NR in our sample, again suggesting group that compared with previous investigations, there was not enough clinical separation between our samples. In addition, the power calculations for sample size were generated on the basis of being able to provide >95% power to detect differences in levels of

### Table 1 Demographic and clinical characteristics by group

| Demographic/clinical variable                      | R               | NR              |
|----------------------------------------------------|-----------------|-----------------|
|                                                   | N   | Mean/ratio | SD | N   | Mean/ratio | SD |
| Age                                                | 54  | 29.52      | 9.36 | 52  | 29.99      | 8.50 |
| Gender (male:female)                               | 54  | 46:8       | –   | 52  | 43:9       | –   |
| Age of illness onset                               | 53  | 26.10      | 6.53 | 50  | 25.31      | 5.93 |
| Illness duration since first antipsychotic (years) | 53  | 3.71       | 6.87 | 50  | 5.03       | 5.79 |
| Duration from first psychotic symptom (years)      | 54  | 4.81       | 7.53 | 52  | 5.50       | 6.13 |
| Duration from first contact with mental health services (years) | 54  | 4.04       | 7.49 | 52  | 5.40       | 6.34 |
| Full time education (years)                        | 53  | 13.09      | 2.37 | 50  | 12.88      | 2.75 |
| Chlorpromazine equivalents (mg/day)                | 53  | 305.45     | 146.86 | 52  | 343.73     | 202.83 |
| PANSS positive score                               | 54  | 12.24      | 3.40 | 42  | 22.65      | 3.54 |
| PANSS negative score                               | 54  | 13.82      | 3.38 | 52  | 20.96      | 4.56 |
| PANSS total score                                  | 54  | 53.46      | 7.91 | 52  | 87.29      | 9.30 |
| CGI positive symptoms score                        | 53  | 3.26       | 0.76 | 52  | 5.50       | 0.10 |
| CGI negative symptoms score                        | 53  | 3.21       | 0.86 | 52  | 4.88       | 1.04 |
| CGI cognitive symptoms score                       | 53  | 3.08       | 0.83 | 52  | 4.83       | 1.22 |
| CGI overall severity                               | 53  | 3.42       | 0.75 | 52  | 5.48       | 0.58 |
| Antipsychotic at assessment                        | 54  | –          | –   | 52  | –          | –   |
|                                                    | Amisulpride=3   | –            | –   | Amisulpride=8 | –     | – |
|                                                    | Aripiprazole=13 | –            | –   | Aripiprazole=10 | –     | – |
|                                                    | Clopixol=2      | –            | –   | Clopixol=1     | –     | – |
|                                                    | Haloperidol=1   | –            | –   | Haloperidol=2  | –     | – |
|                                                    | Olanzapine=19   | –            | –   | Olanzapine=7   | –     | – |
|                                                    | Quetiapine=4    | –            | –   | Quetiapine=9   | –     | – |
|                                                    | Risperidone=9   | –            | –   | Risperidone=6  | –     | – |
|                                                    | Flupentixol=1   | –            | –   | Flupentixol=1  | –     | – |
|                                                    | Paliperidone=2  | –            | –   | Paliperidone=6 | –     | – |
|                                                    | Zuclopenthixol  | –            | –   | acetate=1      | –     | – |

CGI, Clinical Global Impression; NR, antipsychotic non-responder; PANSS, Positive and Negative Syndrome Scale; R, antipsychotic responder.
It is also possible that our definition of antipsychotic response and inclusion criteria may have influenced our findings. As per definition, differences were only observed between groups on CGI-SCH and PANSS measures of symptom severity. Psychotic symptoms such as hallucinations, delusions and paranoia (ie, schizophrenia-like symptoms) have been attributed to D2 dopamine receptors and functioning in the striatum, as evidenced by animal models.65 It has also been reported that following amphetamine administration, hyperactivity of dopamine transition is associated with the activation of psychotic symptoms. However, amphetamine induced psychosis does not tend to exhibit negative and cognitive symptoms.66 In contrast, cognitive deficits in schizophrenia have been reported to be related to dysfunction in the dorsolateral prefrontal cortex (DLPFC).67 68 Glutamate to Gamma Aminobutyric Acid (GABA) ratios in the DLPFC,69 as well as prefrontal glutamate levels in antipsychotic-naïve patients.69 Unlike psychotic symptoms, the Dopamine D1 receptor signalling is essential for cognition.70 Therefore, it is possible that the differences in the neurobiological underpinnings between psychotic and cognitive symptoms may also explain why no cognitive differences were observed between groups, as this was biased in favour of psychotic symptoms due to our inclusion criteria.

Another consideration is that our study focused on younger patients early in their treatment trajectories to reduce the potential effects of chronicity and previous medication, with a mean length of treatment of 3–4 years. Most previous cross-sectional investigations also include older samples with a longer duration of illness.77 78 Differences between psychotic and cognitive symptoms may also explain why no cognitive differences were observed by controls following the first episode.79 Similar to previous studies, our sample of patients being early in their treatment stage may explain why we observed deficits in measures of verbal memory,70 without observing differences relative to controls.71 However, deficits in verbal memory may be less marked at this illness stage.

Likewise, this more restricted focus may explain why previous investigations also showed a lower prevalence of antipsychotic-naïve individuals being diagnosed with a mood disorder prior to antipsychotic treatment. A recent nationwide cohort study also found that on average females are more likely to be first diagnosed at a younger age.74 This coupled with the observation that females also tend to have a later onset of psychotic symptoms than males,75 it is possible that recruiting younger participants may have increased our sample of males and females relative to controls following the first episode.76 Similar to previous studies, our sample of patients being early in their treatment stage may explain why we observed deficits in measures of verbal memory,70 without observing differences relative to controls.71 However, deficits in verbal memory may be less marked at this illness stage.

| BACS measure          | N  | Mean  | SD  | N  | Mean  | SD  | β    | SE  | 95% CI     | P value | β    | SE  | 95% CI     | P value |
|-----------------------|----|-------|-----|----|-------|-----|------|-----|------------|---------|------|-----|------------|---------|
| Verbal memory         | 53 | 38.89 | 10.66 | 50 | 36.9  | 13.04 | -1.99 | 2.34 | -6.63 to 2.66 | 0.398   | -2.68 | 2.38 | -7.41 to 2.05 | 0.263   |
| Digit sequencing      | 53 | 17.87 | 4.95  | 50 | 17.98 | 4.09  | 0.11  | 0.90 | -1.67 to 1.89 | 0.901   | 0.21  | 0.92 | -1.61 to 2.03 | 0.818   |
| Verbal fluency        | 53 | 30.45 | 9.04  | 50 | 31.68 | 9.82  | 1.23  | 1.86 | -2.46 to 4.91 | 0.510   | 1.12  | 1.92 | -2.70 to 4.92 | 0.563   |
| Token motor           | 53 | 66.32 | 14.56 | 49 | 65.90 | 15.26 | -0.42 | 2.95 | -6.28 to 5.43 | 0.886   | -1.05 | 2.93 | -6.87 to 4.78 | 0.723   |
| Symbol coding         | 53 | 47.30 | 11.31 | 50 | 45.46 | 11.83 | -1.84 | 2.28 | -6.37 to 2.68 | 0.421   | -1.71 | 2.35 | -6.37 to 2.95 | 0.469   |
| Tower of London       | 53 | 16.04 | 4.46  | 50 | 16.44 | 3.83  | 0.40  | 0.82 | -1.23 to 2.03 | 0.625   | 0.50  | 0.83 | -1.16 to 2.15 | 0.552   |
| z score composite     | 53 | -2.00 | 1.39  | 49 | -2.03 | 1.51  | -0.03 | 0.29 | -0.60 to 0.54 | 0.922   | -0.04 | 0.30 | -0.63 to 0.56 | 0.908   |
| t score composite     | 53 | 29.91 | 13.81 | 49 | 29.27 | 14.99 | -0.64 | 2.87 | -6.32 to 5.05 | 0.825   | -0.75 | 2.99 | -6.69 to 5.19 | 0.804   |

BACS, Brief Assessment of Cognition in Schizophrenia; NR, antipsychotic non-responder; R, antipsychotic responder.
may have restricted the true picture of schizophrenia at large within the general population.

Despite not detecting significant differences between antipsychotic R groups, it is worth mentioning the importance of conducting research using clinically transferable measures of cognitive impairment. It may be possible for future researchers to use machine learning algorithms to identify subgroups of schizophrenia from cognitive outcomes. Bak et al. used Gaussian mixture modelling to identify two distinct subgroups in antipsychotic-naïve first episode schizophrenia samples. In this study, cognitive and electrophysiological data were used to identify the two groups. When predicting treatment response, assessed by the PANSS, there was a significant predictive relationship between group and antipsychotic response. Therefore, future research should aim to use more machine learning techniques to identify patterns of cognitive performance within schizophrenia subsamples and investigate antipsychotic response between these groups.

CONCLUSIONS

Within this cross-sectional investigation, we observed no differences in cognitive performance between antipsychotic R and NR. This may be because there was less clinical separation between these groups in our sample in comparison to previous investigations. Future investigations should consider the role of machine learning techniques to investigate the role of cognitive functions in identifying subgroups of schizophrenia using first episode cohorts and how this may differ in future stages of treatment resistance. Such research using antipsychotic-naïve patients vs healthy controls has observed strong group discrimination using cognitive measures in comparison to electrophysiology and MRI methods, with other investigations observing distinct subgroups in schizophrenia from differences in early information processing and higher cognitive functions.

Author affiliations

1 Department of Psychiatry Studies, King’s College London Institute of Psychiatry Psychology and Neuroscience, London, UK
2 NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, London, UK
3 Division of Psychology and Mental Health, The University of Manchester, Manchester, UK
4 Greater Manchester Mental Health NHS Foundation Trust and King’s College London, London, UK
5 Psychiatry, The University of Edinburgh Division of Psychiatry, Edinburgh, UK
6 MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK

Contributors

JM, RMM, ODH, AE, KE, RD, LD, JD, AM, TC, JG, CS-P, JW, BD and SLs contributed to the design and implementation of the study. EM completed analyses and wrote the manuscript with the assistance of JM and KE. JM, RMM, ODH, AE, KE, SLs, JD, SLs provided comments on the manuscript. JM is the guarantor.

Funding

STRATA is funded by a grant from the Medical Research Council (MRC) to JM, grant reference MR/L011794. EM’s PhD is funded by the MRC-doctoral training partnership studentship in Biomedical Sciences at King’s College London. JM, KE, RMM, AE and ODH are part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. In the past three years, SLs has received personal support from Sunovion.

References

1 National Institute for Health and Care Excellence. National Collaborating Centre for Mental Health. UK: psychosis and schizophrenia in adults: treatment and management 2014.
2 Elkins H. Treatment-resistant schizophrenia. Psychiatric Clinics of North America 2007;30:511–33.
3 Demjaha A, Lappin JM, Stahl D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med 2017;47:1981–9.
4 Kane JM, Agid O, Baldwin ML, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. 1 J Clin Psychiatry 2019;80:doi:10.4088/JCP.18com12123
5 Üçok A, Çınkırçılı U, Ergül C, et al. Correlates of clozapine use after a first episode of schizophrenia: results from a long-term prospective study. CNS Drugs 2016;30:997–1006.
6 Köhler-Forsberg O, Horsclad HT, Legge SE, et al. Predictors of nonhospitalization and functional response in clozapine treatment: a nationwide, population-based cohort study. J Clin Psychopharmacol 2017;37:148–54.
7 Yoshimura B, Yada Y, So R, et al. The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res 2017;250:65–70.
8 Griffiths K, Millgate E, Egerton A, et al. Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis. Psychother Med 2021;51:378–86.
9 Lally J, Gaughan F, Timms P, et al. Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics. Pharmacogenomics Pers Med 2016;9:117.
10 Gillespie AL, Samanaite R, Mill J, et al. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMJ Psychiatry 2017;17:1–4.
11 Lally J, Ajnakina O, Di Forti M, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med 2016;46:3231–40.
12 Wimberley T, Stovring H, Sørensen HJ, et al. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry 2016;3:358–66.
13 Smart SE, Kypsiakia AP, Murray RM, et al. Predictors of treatment-resistant schizophrenia: a systematic review of prospective observational studies. Psychother Med 2021;51:44–53.
14 Legge SE, Dennison CA, Pardinas AF, et al. Clinical indicators of treatment-resistant psychosis. Br J Psychiatry 2020;216:259–66.
15 Bozzatello P, Bellino S, Roccas P. Predictive factors of treatment resistance in first episode of psychosis: a systematic review. Front Psychiatry 2020;11:522.
16 Smart S. Clinical and genetic predictors of treatment resistant psychosis (Doctoral dissertation, King’s College London 2020).
17 Toulopoulou T, Murray RM. Verbal memory deficit in patients with schizophrenia: an important future target for treatment. Expert Rev Neurother 2004;4:43–62.
18 Fatouros-Bergman H, Cervenka S, Flyckt L, et al. Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia. Schizophr Res 2014;158:156–62.
19 Mesheim-Gately RI, Giuliani AJ, Goff KP, et al. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009;23:315.
20 Kravariti E, Morgan K, Fearon P, et al. Neuropsychological functioning in first-episode schizophrenia. Br J Psychiatry 2009;195:336–45.
21 Snitz BE, MacDonald III AW, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes.
22 Bora E, Özdemir A. Meta-analysis of longitudinal studies of cognition in bipolar disorder: comparison with healthy controls and schizophrenia. Psychol Med 2017;47:2753–66.
23 Fagerlund B, Pantelis C, Jepsen JR. Differential effects of age at illness onset on verbal memory functions in antipsychotic-naïve schizophrenia patients aged 12–43 years. Psychol Med 2020;11.
24 Millgate E, Hode L, Lawrie S. Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a systematic review & meta-analysis. [Manuscript submitted for publication], Institute of Psychiatry, Psychology and Neuroscience, King’s College London.
25 Keefe RSE, Goldberg TE, Harvey PD, et al. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with standard neuropsychological battery. Schizophr Res 2004;68:283–97.
26 Velliger DI, Bow-Thomas CC. Executive function in schizophrenia. Semin Clin Neuropsychiatry 1999;4:24–33.
27 Kravariti E, Dixon T, Frith C, et al. Association of symptoms and executive function in schizophrenia and bipolar disorder. Schizophr Res 2005;74:180–93.
28 Lee J, Park S. Working memory impairments in schizophrenia: a meta-analysis. J Abnorm Psychol 2005;114:599.
29 Forbes NF, Carrick LA, McIntosh AM, et al. Working memory in schizophrenia: a meta-analysis. Psychol Med 2009;39:889.
30 Flanagan MA, Flaum M, Gupta S, et al. Soft signs and neuropsychological performance in schizophrenia. Am J Psychiatry 1996;153:526–32.
31 Bruder GE, Wexler BE, Sage MM, et al. Verbal memory in schizophrenia: additional evidence of subtypes having different cognitive deficits. Schizophr Res 2004;68:247–57.
32 Hill SK, Beers SR, Kmiec JA, et al. Impairment of verbal memory and learning in antipsychotic-naïve patients with first-episode schizophrenia. Schizophr Res 2004;68:127–36.
33 Bokat CE, Goldberg TE. Letter and category fluency in schizophrenic patients: a meta-analysis. Schizophr Res 2003;64:73–8.
34 Ojeda N, Sánchez P, Peña J, et al. Verbal fluency in schizophrenia: does cognitive performance reflect the same underlying mechanisms in patients and healthy controls? J Nerv Ment Dis 2010;198:286–91.
35 Harris MG, McAvinue JW. Sensitivity of attention deficits in schizophrenia. Schizophr Res 2007;91:107–11.
36 Carter JD, Bizzell J, Kim C, et al. Attention deficits in schizophrenia—preliminary evidence of disassociable transient and sustained deficits. Schizophr Res 2010;122:104–12.
37 Rose D, Papoulias C, MacCabe J, et al. Service users’ and carers’ views on research towards stairway care in psychiatry: a qualitative study. BMC Res Notes 2015;8:1–9.
38 American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). American Psychiatric, 2013.
39 Egerton A, Murphy A, Donnici J. Dopamine and glutamate in Antipsychotic-Responsive compared with Antipsychotic- Nonresponsive psychosis: a multicenter position emission tomography and magnetic resonance spectroscopy study (strata). Schizophr Res Bulletin 2020.
40 Kemp R, Haywards Applewhaite G, et al. Compliance therapy in psychotic patients: randomised controlled trial. BMJ 1996;312:345–9.
41 Kemp R, Kirov G, Evertt B, et al. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 1998;172:413–8.
42 Guy W. ECDEU assessment manual for psychopharmacology, US department of health, education, and welfare, public health service, alcohol, drug abuse, and mental health administration, National Institute of mental health, psychopharmacology research branch, division of extramural research programs 1976.
43 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261.
44 Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59:22–33.
45 Opler LA, Kay SR, Lindenmayer JP. Structured clinical interview: the positive and negative syndrome scale (ISCI-PANSS). North Tonawanda, NY: Multi-Health Systems, 1999.
46 Keefe RSE, Harvey PD, Goldberg TE, et al. Norms and standardization of the brief assessment of cognition in schizophrenia (BACS). Schizophr Res 2008;102:109–15.
47 StataCorp LP. Stata statistical software: release 15 College Station, TX, 2017. Available: www. stata.com/features/documentation/ [Accessed 1 Mar 2018].
48 Craik FIM, Bialystok E. Cognition through the lifespan: mechanisms of change. Trends Cogn Sci 2006;10:131–8.
49 Harvey PD. What is the evidence for changes in cognition and functioning over the lifespan in patients with schizophrenia? J Clin Psychiatry 2014;75:34–8.
50 Perlick D, Mattis S, Staastr P, et al. Gender differences in cognition in schizophrenia. Schizophr Res 1992;88:3–9.
51 Han M, Huang X-F, Chen DC, et al. Gender differences in cognitive function of patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012;38:358–63.
52 Cuesta MJ, Peralta V, Zarzuela A. Illness duration and neuropsychological impairments in schizophrenia. Schizophr Res 1998;33:141–50.
53 Bagney A, Rodriguez-Jimenez R, Martinez-Gras I, et al. Negative symptoms and executive function in schizophrenia: do they relationship change with illness duration? Psychopathology 2015;48:262–6.
54 Bulmer MG. Principles of statistics. Courier Corporation, 1979.
55 Lawrie SM, Ingle GT, Santosh CG, et al. Magnetic resonance imaging and single photon emission tomography in treatment-responsive and treatment-resistant schizophrenia. Br J Psychiatry 1995;167:202–10.
56 Smith RG, Kadewar JS, Rosenberg JR. Nonrespones schizophrenia: differentiation by neurologic soft signs and neuropsychological tests. Schizophr Bull 1999;25:813–25.
57 Joober R, Rouleau GA, Lal S, et al. Neuropsychological impairments in neuroleptic-responder vs. nonresponder schizophrenic patients and healthy volunteers. Schizophr Res 2003;23:229–38.
58 de Bartolomeis A, Balletta R, Giordano S, et al. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatr Res 2011;189:86–95.
59 Bourque J, Lakin N, Champagne J, et al. Clozapine and visuospatial processing in treatment-resistant schizophrenia. Cogn Neuropsychiatry 2013;18:615–30.
60 Frydecka D, Beszédi JA, Goicimaki P, et al. Profiling cognitive impairment in treatment-resistant schizophrenia patients. Psychiatry Res 2016;235:133–8.
61 Kravariti E, Demjaha A, Zanelli J, et al. Neuropsychological function at first episode in treatment-resistant psychosis: findings from the ARSEP-10 study. Psychol Med 2019;49:101–8.
62 Huang J, Zhu Y, Fan F, et al. Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: a comparison with matched treatment-responsive patients and healthy controls. Psychiatry Res Neuroimaging 2020;297:111043.
63 Isavoli F, Avagliano C, Altavilla B, et al. Evaluation of a few discrete clinical markers in early stage schizophrenia may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: a study by ROC curve analysis and multivariate analyses. Psychiatry Res 2018;269:481–93.
64 Sosin D, Iwashchenko D, Sozaeva Z, et al. Cognition impairment in patients with treatment resistant schizophrenia: associations with DRD2, DRD3, HTR2A, BDNF and CYP2D6 genetic polymorphisms. Neurol Psychiatr Brain Res 2019;33:48–55.
65 Kellenback C, Simpson EH, Polan HJ, et al. Transient and selective overexpression of dopamine D2 receptors in the striatum creates persistent abnormalities in prefrontal cortex functioning. Neuron 2006;49:603–15.
66 Voce A, Calabria B, Burns R, et al. A systematic review of the symptom profile and course of methylphenidate-associated psychosis. Subst Use Misuse 2021;56:635–48.
67 Miller EK, Cohen JD. An integrative theory of prefrontal cortex dysfunction. Annu Rev Neurosci 2001;24:167–202.
68 Schoonover KE, Dienel SJ, Lewis DA. Prefrontal cortical alterations of glutamate and GABA neurotransmission in schizophrenia: insights for rational biomarker development. *Biomark Neuropsychiatry* 2020;3:100015.

69 Bojesen KB, Broberg BV, Fagerlund B, et al. Associations between cognitive function and levels of glutamatergic metabolites and gamma-aminobutyric acid in antipsychotic-naive patients with schizophrenia or psychosis. *Biol Psychiatry* 2021;89:278–87.

70 Arnsten AF. Catecholamine modulation of prefrontal cortical cognitive function. *Trends Cogn Sci* 1998;2:436–47.

71 Chan SK, Chan HY, Honer WG. Predictors of treatment-resistant and Clozapine-Resistant schizophrenia: a 12-year follow-up study of First-Episode Schizophrenia-Spectrum disorders. *Schizophrenia Bulletin* 2020.

72 Zanelli J, Mollon J, Sandin S, et al. Cognitive change in schizophrenia and other psychoses in the decade following the first episode. *Am J Psychiatry* 2019;176:811–9.

73 Barder HE, Sundet K, Rund BR, et al. Ten year neurocognitive trajectories in first-episode psychosis. *Front Hum Neurosci* 2013;7:643.

74 Sommer IE, Tiihonen J, van Mourik A, et al. The clinical course of schizophrenia in women and men—a nation-wide cohort study. *NPJ Schizophrenia* 2020;6:1–7.

75 Ochoa S, Usall J, Cobo J, et al. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. *Schizophr Res Treatment* 2012;2012:1–9.

76 Bak N, Ebdrup BH, Oranje B, et al. Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology. *Transl Psychiatry* 2017;7:e1087.

77 Ebdrup BH, Axelsen MC, Bak N, et al. Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naive schizophrenia patients. *Psychol Med* 2019;49:2754–63.
STRATA: Investigating factors associated with response to antipsychotic treatment
Protocol. Version 4.0, 19th August 2016
REC REF: 15/LO/0038

STRATA: Investigating factors associated with response to antipsychotic treatment

Sponsor
Name of organisation: King's College London
Address: Room 1.8 Hodgkin Building, Guy's Campus, London SE1 4UL
Telephone: 020 7848 6960
Fax:
Email: keith.brennan@kcl.ac.uk

Chief Investigator
Name: Dr James MacCabe
Address: Institute of Psychiatry, Psychology & Neuroscience (IoPPN), De Crespigny Park, SE5 8AF
Telephone: 02078480757
Fax:
Email: james.maccabe@kcl.ac.uk

Name and address of Principal Investigator (on grant award).

Name: Prof Shitij Kapur
Address: Institute of Psychiatry, Psychology & Neuroscience (IoPPN), De Crespigny Park, SE5 8AF
Telephone: 020 7848 0593
Fax:
Email: shitij.kapur@kcl.ac.uk

Name and address of lead Co-Investigators at sites

Name: Prof Shon Lewis
Address: The University of Manchester, University Place, Oxford Road, Manchester, M13 9PL
Telephone: 0161 306 7944
Fax:
Email: shon.lewis@manchester.ac.uk

Name: Prof Mick O'Donovan
Address: MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Henry Wellcome Building, Heath Park, Cardiff, CF14 4XN
Telephone: (029) 20687066
Fax:
Email:odonovanmc@cardiff.ac.uk
STRATA: Investigating factors associated with response to antipsychotic treatment
Protocol. Version 4.0, 19th August 2016
REC REF: 15/LO/0038

Name: Prof Stephen Lawrie
Address: University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, EH10 5HF
Telephone: 0131 537 6671
Fax:
Email: s.lawrie@ed.ac.uk
STRATA: Investigating factors associated with response to antipsychotic treatment Protocol. Version 4.0, 19th August 2016
REC REF: 15/LO/0038

CONTENTS

1. Introduction

2. Study Objectives and Design

2.1. Study Objectives

2.2 Study Design

3. Sample Size, Statistics, Selection and Withdrawal of Subjects

4. Study procedures

5. Sample Handling and Laboratories

6. Assessment of Safety

7. Study oversight arrangements

8. Ethics and Regulatory Approvals

9. Data Handling

10. Finance & Publication Policy
STRATA: Investigating factors associated with response to antipsychotic treatment
Protocol. Version 4.0, 19th August 2016
REC REF: 15/LO/0038

**Study Synopsis**

| Full Title | Investigating factors associated with response to antipsychotic treatment |
|------------|-------------------------------------------------------------------------|
| Short Title/Acronym | STRATA |
| Protocol Version number and Date | Version 4.0, 19th August 2016 |
| Study Duration | 36 months |
| Study Design | Basic Science |
| Sponsor/Co-sponsors | Kings College London / South London and Maudsley NHS Foundation Trust |
| Chief Investigator | Dr James MacCabe |
| REC number | 15/LO/0038 |
| Primary objective | The principle objective is to use Positron Emission Tomography (PET), Magnetic Resonance Spectroscopy (MRS), genetic and clinical data to confirm recent evidence of a distinct subtype of schizophrenia, based on differences in dopamine and glutamate function which would lead to developing a clinically useful, acceptable and cost-effective stratification tool. |
| Secondary objective (s) | To establish a lasting network of academia and industry partners and patients databases to facilitate and expedite both follow-up and novel research built to address patient stratification. To examine and improve test-re-test and intercentre reliability of neuroimaging procedures for future large scale multisite studies in this mould that will be conducted. |
| Number of Subject | 100 |
| Main Inclusion Criteria | aged 18-65; DSM 5 schizophrenia/schizophreniform disorder. |
Summary statistics will be used to describe the demographic and clinical characteristics of each participant group.

Group differences in demographic, clinical variables and 18F-DOPAKi and glutamate concentration will be determined using pre-specified between group comparisons as appropriate (e.g. Chi square; Fischer's Exact; ANOVA).
1. Introduction

People with schizophrenia suffer from a range of symptoms including hallucinations (such as hearing voices), delusions (false beliefs) and thought disorder (thoughts not flowing in a logical way), as well as 'negative symptoms' such as a lack of motivation and withdrawal from social contact. Currently, antipsychotic medication is the mainstay of treatment for schizophrenia and all existing antipsychotic medications are thought to work by acting to reduce transmission of a brain chemical called dopamine. However, even after attempts to treat the disorder with two different antipsychotics, around 30% of patients still fail to improve. When this happens, the medical guidelines recommend treatment with a different drug called clozapine. However clozapine has several side effects and requires regular blood tests, so people do not like taking it. It is also ineffective in some patients.

The result is that a large number of patients spend too long on ineffective drugs which impact greatly on their mental health, well-being and quality of life whilst the cost of ineffective treatment is a huge financial burden to the NHS, consuming 25-50% of the total national mental health budget.

STRATA (funded by a £5M Medical Research Council award) aims to build on new evidence from neuroimaging and genetics studies suggesting that those who do not respond may actually have a completely different neurochemical abnormality causing their symptoms (the same sort of symptoms as are caused by excessive dopamine), involving a different chemical called glutamate. There are some new medicines under development that we hope will help people whose illness has not responded to standard medicines acting on dopamine.

We aim to develop a method to predict, even as early as when first seen, which patients will respond to standard dopamine drugs, and which people are instead more likely to respond to the new glutamate drugs. This will allow people to receive the medicines they need straight away, without having to try ineffective drugs first.

The proposed research programme is broken down into several parts. This protocol describes the first study, which is a UK, multicentre study using brain scans to confirm that those patients who don't respond to standard treatments have higher glutamate levels, but lower dopamine levels than those who respond well. This information, along with clinical and genetic information, will be used to develop tests to identify in advance which people will respond to dopaminergic versus glutamatergic medication.

2. Study Objectives and Design

2.1. Study Objectives and Outcomes

The principle objective is to use Positron Emission Tomography (PET), Magnetic Resonance Spectroscopy (MRS), genetic and clinical data to confirm recent evidence of a distinct subtype of schizophrenia, based on differences in dopamine and glutamate function which would lead to developing a clinically useful, acceptable and cost-effective stratification tool.

The secondary research objectives are:
STRATA: Investigating factors associated with response to antipsychotic treatment
Protocol. Version 4.0, 19th August 2016
REC REF: 15/LO/0038

i) To establish a lasting network of academia and industry partners and patient databases to facilitate and expedite both follow-up and novel research built to address patient stratification.

ii) To examine and improve test-re-test and intercentre reliability of neuroimaging procedures for future large scale multisite studies in this mould that will be conducted.

The study is designed to generate a predictive test for treatment response so the outcome will be the overall measure generated. The data that will lead to this will include MRS glutamate level, the PET Ki value, polygenic risk score and clinical variables such as PANSS score.

2.2 Study Design
STRATA is a multi centred study. 100 participants will be recruited across 4 university research sites including KCL, University of Manchester, Cardiff University, and University of Edinburgh.

Participants will consent to all aspects of the study including interviews/assessments, blood and urine sampling, MRI scan and PET scan (the latter in London and Manchester only) but can also choose to opt out of some tasks if necessary.

1. Assessments
An initial interview will collect demographic and personal information (e.g. address, contact details, date of birth, gender, handedness, head injury and other relevant medical history), and structured assessments of medication history and response. Clinical information will also be recorded from medical records. The Mini International Neuropsychiatric Interview (MINI) will be used to confirm diagnosis, which takes around 15 minutes to complete.

Illness severity will be measured using:
   i. Positive and Negative Syndrome Scale (PANSS),
   ii. Clinical Global Impression scale (CGI -SCH)
   iii. Kemp Clinician Rating Scale (of adherence to treatment)
   iv. Brief Assessment of Cognition in Schizophrenia (BACS)

2. Biological samples
Blood samples will be collected via cannula (as described under the PET scan section below) or by venous puncture, during a routine blood sample whenever possible. The participant will give up to 50ml in blood (around 3 tablespoons), this is in line with sampling guidelines.

While the biological sample collection is ongoing, samples will be stored at the laboratory corresponding to each research site. The samples for genetics analysis will subsequently be transferred to the MRC Center for Neuropsychiatric Genetics and Genomics, Cardiff University.

KCL/South London and the Maudsley (SLaM) participants will also be invited to participate in the BRC Biobank. This is covered by a separate ethical approval (09/H0606/84 NRES Committee South Central-Oxford C.)
Participants will be asked to provide samples (urine and blood) for metabolomics analysis. This will be processed at MRC-NIHR National Phenome Centre. The Centre is funded by the MRC and NIHR and led by Imperial College London and King's College London.

As of April 2016, participants will also have a sample taken for proteomic analysis. These samples will be sent to the University of Manchester (Molecular Pathology Innovation Centre). This will be within the 50ml sampling guideline already approved.

3. Magnetic Resonance Imaging (MRI)

The MRI scans (100 in total) will take place at four locations (London, Cardiff, Manchester and Edinburgh) at NHS Trust or University sites. The MRI session will last a maximum of 1 hour. During the scan, participants will be asked to lie flat on their back with their head inside the scanner. The scanner makes a loud noise as it takes pictures, so participants will be given headphones to wear and asked to lie as still as possible. The researcher will be able to speak to the participant over the microphone throughout and participants will be told if they do feel uncomfortable the session can be stopped at any time. The MRI scan itself is painless and safe. Some people find scans claustrophobic or anxiety-provoking, and we have a mock scanner that participants can try out first. The scanner consists of a powerful magnet, which may attract metal objects. Therefore before the scan participants will go through a safety questionnaire, to check that they can have the scan. If a participant has any metal in their body, either from accidents or operations, they may not be able to have the MRI scan, but they can still take part in the rest of the study.

All data collection will occur at 3 Tesla. During the scan, data acquisition will include acquisition of localizer, T1-weighted and T2-weighted structural scans. 1H-MRS data for measurement of regional concentrations of glutamate and other metabolites present in the 1H-MRS spectra will be acquired using conventional PRESS (Point RESolved Spectrocopy) acquisition routines, as well as a resting state fMRI sequence if time allows.

Due to change of scanner at Cardiff University, participants recruited in Cardiff prior to the decommissioning of the old scanner will be re-contacted and asked whether they would volunteer for a second MRI scan on the new scanner. They will also be asked to repeat some of the interview/assessments and may be asked for biological samples (only in circumstances where these were not provided previously). Participants will be reimbursed for their time at the same rate.

In the unlikely event that MRI scanner issues or excessive movement make the MRS data unusable at other sites, participants can be re-contacted and asked whether they would like to volunteer for a second scan.

4. Positron Emission Tomography (PET)

The PET scans (60 in total, subset of those having MRI scans) will take place at two sites: i) Imanova Limited, Imperial College London, Hammersmith Hospital in London. ii) The Wolfson Molecular Imaging Centre in Manchester.

PET with the radiotracer 18F-DOPA will be used to assess brain dopaminergic function in a subset of participants (N=60) recruited at KCL and University of Manchester. The PET scan procedure involves an initial transmission scan followed by a dynamic scan lasting approximately
90 minutes after injection of the radiotracer 18F DOPA through a cannula inserted into an arm vein. In the event the participant has to get off the scanner e.g. to go to the toilet or for some other reason then the transmission scan may be repeated to reposition them in the camera. In the unlikely event of technical failure prior to or during the PET scan the subject will be invited back for a replacement session (the total dose will then be ~7.5mSv, and the risks of this will be explained).

In Manchester, participants will be offered the option of having an extra, High Resolution Research Tomograph (HRRT) scan after their main STRATA PET scan (after a 15 minute comfort break). This will be between 30-60 minutes depending upon participant tolerability. Due to the long half-life of 18F and the slow removal of 18F from the brain, this extra scan will not involve any further injection of radiotracer. Another transmission scan will be carried out for attenuation correction purposes although this will be of very low radiation dose (0.02mSv). In the event of significant head movement during the HRRT scan, this transmission scan may be repeated.

In order to minimise the peripheral breakdown of 18F-DOPA, an oral dose of 150mg carbidopa and 400mg entacapone will be given one hour prior to the scan. Very few people experience any side-effects from these. Very occasionally people experience stomach upset, muscle movements, dry mouth and/or an orange tinge to their urine from the tablets, which may last a few hours to a day. This permits the use of a lower dose of 18F-DOPA than would otherwise be necessary. Participants will be asked to refrain from eating, drinking (apart from water) and smoking from midnight on the night before the scan, until after the scan is finished. This is because large amino acids may affect brain uptake of 18F-DOPA. Participants will also be instructed not to take illicit drugs (such as cannabis or cocaine) in the prior three days. Before the scan we will ask for a urine sample to check whether substances that can affect the scan are in their system. Women of childbearing age will have a pregnancy test and will be required to use regular contraception prior to the scan. At the start of the scan we will give participants a radiotracer (which is mildly radioactive) to measure the brain dopamine system. At the end of the scan the cannula will be removed from their arm.

Participants taking part in a PET scan at Imanova (SLaM/KCL participants) will have an additional 1-2 tablespoons (up to 30ml) of blood taken through their cannula to measure natural blood chemicals (hormones and genes) that are connected to dopamine function.

Participants taking part in a PET scan in Manchester will have all their bloods taken at this point (up to 50ml) as described under ‘Biological Samples Section’, whenever possible.

**3. Sample Size, Statistics, Selection and Withdrawal of Subjects**

The patients will be identified by members of the clinical team. Only the clinical team (who may also be part of the research team with NHS honorary contracts) will be able to access participant records and data prior to consent. No patient records will be screened by study researchers prior to consent. Study researchers will have access to patient records after/ if participants have consented to this.

We will recruit a total of 100 participants. Potential participants may be referred via clinical teams or other research studies/existing databases with consent to re-contact or registries and recruitment initiatives in NHS Trusts whose terms are in accordance with NHS Trust policies.
Participants will be first approached by a member of the clinical team or a member of the research team, with approval from the clinical team/other study.

Inclusion Criteria

1) aged 18-65;
2) DSM 5 schizophrenia/schizophreniform disorder.
3) Participants must read and write in English at a level sufficient to understand and complete study-related procedures

Exclusion Criteria

1) Pregnancy;
2) Severe head injury involving loss of consciousness >5 minutes (ever);
3) Meeting ICD criteria for harmful substance misuse or psychotic disorder secondary to substance misuse;
4) Participation in MRI scans requires exclusion of contraindications to MRI at 3 tesla e.g. metallic or electronic implants;
5) Severe claustrophobia.
6) Treatment with clozapine in the last 3 months

To establish and confirm the stratifier 1H-MRS data will be acquired in a total of 100 patients early in the course of their treatment; 50 T-Resp and 50 T-NonResp; matched for chronicity of illness.

Operational definition of T-Resp:
(i) treatment with only one antipsychotic drug since onset, or treatment changes have been due to adverse effects, not for non-response. (ii) CGI-SCH severity score of <4; (iii) PANSS total <60 (Leucht 2005); (iv) CRS >3

Operational definition of T-NonResp:
(i) documented treatment with at least two antipsychotics each above the minimum therapeutic dose as defined by the BNF for >4 weeks each; (ii) despite ongoing treatment and adequate adherence (assessed by iv) a CGI-SCH severity score of >3; (iii). PANSS total severity rating of at least 70 iv) Clinician Rating Scale (CRS; a measure of adherence) (Kemp et al 1996) >3.

Power and sample size calculation:
The study is powered to give >95% power to detect differences found in Egerton et al 2012 (α=0.05, allowing for 10% loss of sensitivity due to combining data from multiple centres). We have more than 80% power to detect a significant difference between a ROC curve with AUC 0.7 and chance, assuming α=0.05, 2-tailed. Two-tailed 18F-DOPA PET data will be acquired in a subset at 2 sites (N=60) to determine if the double dissociation between DA function and GLU function we have seen in chronic patients is also evident early in the illness course, where the strategy is most likely to be used (T-Resp n=30, T-NonResp n=30; powered to give >95% power to detect differences found in Demjaha et al 2012; α=0.05, allowing for 10% loss of sensitivity due to combining data from multiple centres).

Summary statistics will be used to describe the demographic and clinical characteristics of each participant group.
Group differences in demographic, clinical variables and 18F-DOPA Ki and glutamate concentration will be determined using pre-specified between group comparisons as appropriate (e.g. Chi square; Fischer’s Exact; ANOVA).

Missing data will be minimal given that data is being collected prospectively. The exact reason for the missing data will be recorded. Any blank measures or spurious data will be checked against the paper copy of the CRF stored securely at sites.

Participants will be clearly told they can withdraw from the study at any time without having to give a reason. This is clear in the information sheet and the researcher will also explain this verbally to participants during the informed consent process. If a participant wishes to withdraw from a study all their identifiable data will be destroyed. Data or tissue already collected with the consent, which is not identifiable, would be retained and used in the study. No further data or tissue would be collected or any other research procedures carried out on or in relation to the participant.

Control group
We will recruit up to 15 healthy volunteers aged 18-65 to be scanned at each PET site (two sites; Imanova Limited, Imperial College London and The Wolfson Molecular Imaging Centre in Manchester) and 10 healthy volunteers aged 18-65 to be scanned at each MRI site (4 sites). This is to determine inter-site scanner variability and to provide normal range data for comparison with the clinical groups. In addition to the exclusion criteria above, healthy volunteers will be excluded if there is a history of schizophrenia or other psychotic disorder. Healthy volunteers will be recruited using an existing database of interested potential participants held at KCL.

4. Study procedures

Informed Consent

1) Participants will be first approached by a member of the clinical team or a member of the research team, with approval from the clinical team.

2) The study will be described verbally to potential participants and they will be given a copy of the information sheet. They will be encouraged to ask questions about the research. Potential participants will be allowed as much time as they require to make a decision and at least 24 hours so they are able to seek advice from others about participation, including previous participants in the research where possible.

3) If a patient expresses an interest in taking part, capacity to consent will be assessed and documented by the research team, in consultation with the clinical team.

4) If the patient has capacity to consent and agrees to participate in the study, they will be asked to sign and date two copies of the consent form. One copy will be kept by the participant and one by the research team. The research team will pass onto the clinical team to scan into medical notes, or incorporate in paper notes.

5) The participant will be informed that they can withdraw consent at any time, and without giving a reason.

6) Participants will be informed they are to be compensated for their time and travel expenses. This monetary amount will be up to £120 (£145 in Manchester) depending on which parts of the study the participant is involved with.
Within Avon and Wiltshire Mental Health Partnership NHS Trust, Everyone Included will be used to identify potentially eligible participants. Potentially eligible participants are identified based on the study inclusion/exclusion criteria, excluding those who have declined to receive information. This is done via an automated search of the Trust’s electronic patient record system (RiO). An authorised search will be requested by a member of the R&D department, who are part of the clinical team and carried out by a member of the Information Analysis team. A data set is returned directly to the Everyone Included Administrators for processing the letters. No patient identifiable data will ever leave the Trust or be accessed by an external research team during this process.

The ‘Research Opportunity Letter’ will be sent to these individuals. The letter itself will not contain any patient identifiable or disclosing information (such as making reference to their diagnosis or medications). It will provide a free-post return slip and contact details (phone, email, website, postal address) inviting individuals to get in touch if they would like to further information / to take part. The onus is on the individual to express an interest, otherwise no further action is taken.

Upon responding to the ‘Research Opportunity Letter’, a Participant Information Sheet will be provided. If the research team is external, the individual will be asked if they are happy for their details (i.e. name and phone number) to be passed directly to the research team. No information is ever accessed by or passed to an external research team without first gaining permission from the potential participant. At this point standard study recruitment processes proceed.

Risks and burdens
The questionnaires involve personal questions and recalling experiences that some people may find distressing. Participants will be told if they feel uncomfortable with any of the questions they do not have to answer them.

Blood sampling and placing the cannula can cause some discomfort, and there is a possibility that a small bruise may develop. This task will be performed by research workers trained in phlebotomy. Any risks of infection will be contained by using standard sterile procedures and the risks associated with this task will be the same as for any other blood sample collection.

Any participants who become distressed during any procedure involved in this study will be encouraged to pause and will be reminded routinely that they can withdraw from the study at any time without a reason or penalty.

Any clinically significant issues that may arise during the assessment, the verbal consent will be obtained from the patient to pass onto the responsible psychiatrist or other relevant member of the staff. This will always be done with the participants’ permission and will only be breached in the rare cases when there is judged to be an issue of safety, for example if the participant makes specific threats towards an individual.

Imaging
The MRI and PET scans themselves are painless and safe. Some people find the scans claustrophobic or anxiety-provoking. There is a mock scanner that participants can try out first if they wish. Participants will be told if they feel uncomfortable the scanning can be stopped at any time. Before the scan we will go through a safety questionnaire, to check that participants can have the scan. If they have any metal in their body, either from accidents or operations, they may
STRATA: Investigating factors associated with response to antipsychotic treatment
Protocol. Version 4.0, 19th August 2016
REC REF: 15/LO/0038

not be able to have the MRI scan, but they can still take part in the rest of the study. Clinical Research workers and research workers will log screening results.

Very occasionally people experience side effects from the medication they receive when taking part in a PET scan. These side-effects can include stomach upsets, muscle movements, dry mouth and/or an orange tinge to their urine. These side-effects may last a few hours to a day but participants will be warned about this and told it is nothing to worry about.

PET scans involve a small amount of radiation. Any exposure to radiation carries a risk of damaging the body's tissues and possibly triggering cancer at a later date. However, the risk is very small. A standard PET scan in this study will expose participants to 3.7mSv, (this may be 3.72mSv in Manchester if participants decide to have the extra, high resolution PET scan), which is the same amount of radiation that they are exposed to from natural sources of radiation, such as the sun, over the course of 18 months. In extremely rare cases the PET scan may need to be repeated and we have ARSAC approval for a maximum of 7.5mSv exposure per participant. Most experts believe that the risk of cancer developing only becomes significant in people who are exposed to 100mSv or more. However, as a precaution we are excluding pregnant or breastfeeding women. A pregnancy test will be carried out on female urine samples before the PET scan is conducted. Participants will be asked to consent to this on the consent form. Clinical Research workers and research workers will log screening results and ensure participants will not be exposed to more than 10mSv in 12 months (ARSAC guidelines suggest 10mSv as the normal upper limit for radiation exposure related to research procedure).

5. Sample handling and laboratories

Biological sample collection tubes and barcodes will be sent to sites in advance from the MRC Center for Neuropsychiatric Genetics and Genomics, Cardiff University. Samples will be stored in laboratories at sites and transportation will be organized when required (likely at 6 monthly basis, dependent on recruitment). Details of sample collection and storage at site will be recorded. Study SOPs will describe collection and storage specifications to ensure all sites are following the same guidelines.

When samples arrive at Cardiff University, researchers will ensure that the physical integrity of these samples have not been compromised in transit and track the samples in using their barcodes. The research team at Cardiff will notify the sponsor and the other study teams of any issues in transportation.

Cardiff University will extract DNA from the blood. We will perform genome-wide and targeted genotyping and/or exome or whole genome sequencing. We will seek genetic association with the imaging and other outcome measures at the level of individual genotype/sequence variant, genes, gene sets/pathways and polygenic or other summary scores.

A urine and blood sample will undergo metabolomic analysis at MRC National Phenome Centre. The Centre is funded by the MRC and NIHR and led by Imperial College London and King's College London. An additional blood sample will undergo proteomic analysis at the University of Manchester.

KCL/South London and the Maudsley (SLaM) participants will also be invited to participate in the BRC Biobank. This is covered by a separate ethical approval (09/H0606/84 NRES Committee South Central-Oxford C.)
6. Assessment of Safety

There are no serious adverse events expected to occur during the study.

All blood samples will only be taken by researchers trained in phlebotomy. All risks are the same as for any routine blood sample and are therefore minimal.

The drugs administered and the radiotracer used for the PET are standard procedures. The drugs administered may cause stomach upsets, muscle movements, dry mouth and/or an orange tinge to their urine. These side-effects may last a few hours to a day but participants will be warned about this and told it is nothing to worry about. Female participants will have a pregnancy test in advance.

For MRI scans a safety questionnaire will be carried out prior to the scan to check the participant does not have any metal in their bodies from operations or accidents.

7. Study oversight arrangements

STRATA is a multi-centred study and this will be managed by attendance at a monthly Consortium Executive meeting which will be responsible for the effective oversight of the daily activities of the study. Quarterly Consortium Board (CB) teleconferences will oversee the progress of, and interaction between, the workstreams to maintain communication of issues and progress between sites across the different aspects of STRATA. The CB will submit six-monthly Programme reports to the funder, MRC.

The project team consists of a full time Project Manager based at the IoPPN, KCL and a 50% Project Manager at the University of Manchester.

8. Ethics & Regulatory Approvals

REC name and address: South East Coast-Surrey Research Ethics Committee, Whitefriars, Level 3, Block B, Lewins Mead, Bristol, BS1 2NT

This study has also been reviewed and approved by the Administration of Radioactive Substances Advisory Committee (ARSAC).

9. Data Handling

Once participants have consented to be in the study some personal details will be taken. These details will be taken by the researcher with full consent to do so. These details will be kept securely at sites and used to contact patients when required to make appointments. No personal data will be shared with anyone outside of that study team. Each participant will be given a unique identifier and any clinical or genetic or imagining data relating to the same participant will link via that code.

Data will be entered and stored on a secure web application called Research Electronic Data Capture (REDCap). REDCap will not store any personal details and all participants will have a unique non-identifiable ID code. This unique ID code will then be used to merge all processed imaging, genetics and clinical data. REDCap will be hosted on secure servers at the Biomedical
STRATA: Investigating factors associated with response to antipsychotic treatment
Protocol. Version 4.0, 19th August 2016
REC REF: 15/LO/0038

Research Centre at Kings College London. All sites can access REDCap for the purposes of data entry via a web browser and data is uploaded when a WIFI signal is available.

The CI will ensure that the trial is conducted in compliance with the principles of the Declaration of Helsinki (1996), and in accordance with all applicable regulatory requirements including but not limited to the Research Governance Framework, Trust and Research Office policies and procedures and any subsequent amendments.

10. Finance and Publication Policy
STRATA is funded by a £4,900,000 Medical Research Council grant. Kings College London will receive and manage this funding. A collaboration agreement has agreed budgets between sites.

Analysis and findings from the study will be published as papers in journals. No identifiable data will be included.

This study has been adopted onto the UKCRN Portfolio and the research project will be registered on their database which is publicly available.
## Supplementary material

### Table S.1

**Univariable and multivariable linear regression models for response status and BACS performance**

| BACS measure       | N    | NR   | Unadjusted | Adjusted for age, gender, illness duration and anticholinergic effects | Adjusted for anticholinergic effects |
|--------------------|------|------|------------|------------------------------------------------------------------------|--------------------------------------|
|                    |      |      | β     | SE  | 95%CI   | P-value | β    | SE  | 95%CI   | P-value | β    | SE  | 95%CI   | P-value |
| Verbal Memory      | 53   | 50   | -1.99 | 2.34| -6.63 ; 2.66 | .398   | -3.18 | 2.38| -7.90 ; 1.54 | .185   | -2.34 | 2.35| -7.00 ; 2.32 | .322   |
| Digit Sequencing   | 53   | 50   | 0.11  | 0.90| -1.67 ; 1.89 | .901   | 0.07  | 0.92| -1.76 ; 1.89 | .944   | -0.02 | 0.90| -1.81 ; 1.77 | .983   |
| Verbal Fluency     | 53   | 50   | 1.23  | 1.86| -2.46 ; 4.91 | .510   | 1.08  | 1.94| -2.78 ; 4.94 | .580   | 1.17  | 1.88| -2.56 ; 4.90 | .536   |
| Token Motor        | 53   | 49   | -0.42 | 2.95| -6.28 ; 5.43 | .886   | -1.40 | 2.97| -7.29 ; 4.50 | .638   | -0.62 | 2.99| -6.56 ; 5.31 | .835   |
| Symbol Coding      | 53   | 50   | -1.84 | 2.28| -6.37 ; 2.68 | .421   | -1.89 | 2.37| -6.60 ; 2.83 | .428   | -2.04 | 2.30| -6.60 ; 2.53 | .378   |
| Tower of London    | 53   | 50   | 0.40  | 0.82| -1.23 ; 2.03 | .625   | 0.35  | 0.84| -1.30 ; 2.01 | .672   | 0.23  | 0.82| -1.40 ; 1.85 | .782   |
| z score composite  | 53   | 49   | -0.03 | 0.29| -0.60 ; 0.54 | .922   | -0.08 | 0.30| -0.68 ; 0.52 | .798   | -0.07 | 0.29| -0.65 ; 0.50 | .800   |
| t score composite  | 53   | 49   | -0.64 | 2.87| -6.32 ; 5.05 | .825   | -1.33 | 3.02| -7.32 ; 4.67 | .662   | -1.24 | 2.88| -6.96 ; 4.48 | .668   |

*Note. R = antipsychotic responder; NR = antipsychotic non-responder; BACS = Brief Assessment of Cognition in Schizophrenia; CIs = confidence intervals.*